Ganymed Pharmaceuticals Ag

Johannes Gutenberg-universität Mainz

Astellas Pharma Gmbh

Ganymed Pharmaceuticals Gmbh

Tron—translationale Onkologie an Der Universitátsmedizin Der Johannes Gutenberg—universität Mainz Gemeinnützige Gmbh

Johannes Gutenberg Universität

Tron—translationale Onkologie an Der Universitat

Johannes Gutenberg-universität Mainz, Vertreten Durch Den Präsidenten

Gunda Brandenburg

Ugur Sahin

Dirk Usener

Harald-Gerhard Geppert

Stefan Fritz

Anja Kristina Schröder

Phillippe Thiel

Christoph Uherek

Özlem Türeci

Ozlem Tureci

Oezlem Tuereci

Anja Kristina Schroder

Philippe Thiel

Cristoph Uherek

Anja Kristina Schroeder

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.

Monoclonal antibodies against Claudin-18 for treatment of cancer

Monoclonal antibodies against claudin-18 for treatment of cancer

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD1 8, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, cancer of the gallbladder, and the metastases thereof.

Growing community of inventors

Mainz, Germany

Gunda Brandenburg